Immix Biopharma Investor Presentation Deck
N-GENIUS Platform + IMMIXBio™ SMARXT Tissue-Specific™ Platform
HIM
N-GENIUS PLATFORM
3 Key Elements
Purpose-Built Cell Therapy Evidence Capture
Engine + Relational Database
Relating Nexcella internal data to external to accelerate
therapy design, manufacture, and preclinical
Proprietary EXPAND technology
Applied to multiple cell therapy indications, already utilized
to create NXC-201, to potentially increase efficacy and
tolerability
Atomized, Novel Binding Scaffold
Generation Engine
Allows us to make the correct binding for every molecule
Source: Development and manufacturing of novel locally produced anti-BCMA CART cells for the treatment of
relapsed/refractory multiple myeloma: phase I clinical results. Haematologica. 2022 Oct 6. doi:
10.3324/haematol.2022.281628. Epub ahead of print. PMID: 36200421.
TME Normalization™ Technology - SMART
Tissue-Specific Platform Oncology Application
3 Pillars
Benefit
●●●
IMMIX
S BIOPHARMA
1 System-Tissue Biology Model Development
2
3
Purpose-Built Physical Biochemistry Engine
Predictive Validation Framework
Robust MOAS in Complex Pathologies
Generate Actionable Drug Candidates
Highly Predictive IND-Enabling Activities
19View entire presentation